Skye Bioscience Inc (SKYE)

[Closewatcher]

Did some digging...some exciting stuff ahead.

Its silly to compare biotechs that are targeting different therapies so its not entirely Apples to Apples but in the case of Zynerba, you have them operating at a 250 million market cap right now with just a couple of trials underway. Their pipeline is less robust as Nemus: http://zynerba.com/in-development/

Dating back their press releases, Phase 1 trials for just one target (Epilepsy) were underway in November 2015. They never dipped below a 50 million market cap with that 1 trial underway, and over the course of 2016 initiated a few more trials and had success in Phase 1 trials + 1 phase trial giving momentum to the current levels.

The pathway to these levels is clear and will start with NB1111 glaucoma Phase 1 trials. Phase 2 trials were indicated to take only 28 days for this target in a recent press release, so youre talking about a rapid progression once it actually starts.

Can it be December 2017 yet?